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ABSTRACT
Background: Uric acid  a  metabolic end  product  of  purine  degradation  is implicated  in  gout  as  aetiology.  Its
increased levels have also been associated with hypertension, cardiovascular morbidity and mortality. Few studies
have been conducted, especially in India to elucidate association of uric acid with prehypertension.
Aims: This study intends to assess the association of serum uric acid levels with blood pressure in normotensive,
prehypertensive and hypertensive population. It also intends to check whether there is an incremental rise of serum
uric acid with increasing blood pressure. Material and methods: Two hundred outpatients who met inclusion and
exclusion  criteria  and  consented  formed  study  population.  Blood  pressure  of  each  participant  was  measured
followed by venipuncture to collect venous blood for measurement of serum uric acid. Participants were categorised
into 4 groups as Normal, Prehypertension, Hypertension –Stage 1, Hypertension Stage -2 as per Joint National
Committee 7 classification. Data was analysed to know levels of serum uric acid among the four categories and to
verify association of uric acid with blood pressure. Results and Conclusions: Stepwise increase in serum uric acid
levels was observed along with increasing blood pressure. Strong positive linear correlation was observed between
serum uric acid levels and mean blood pressure (Pearson’s correlation coefficient r = 0.74; p< 0.0001). Uric acid
was associated (r = 0.442) with blood pressure in prehypertension population. Serum uric acid levels are associated
with prehypertension and hypertension and are independent and strong predictors of cardiovascular mortality.
Keywords: Blood pressure, Prehypertension, Uric acid.
INTRODUCTION
Uric acid is an end product of purine degradation in
humans  and  is  primarily  excreted  through  urine.
Serum uric acid levels are regulated by dietary purine
intake,  endogenous  metabolism  of  purines,  and  its
urinary excretion rate. In the process of evolution 15
million  years  ago,  two  mutations  rendered  uricase
gene  non-functional  in  humans  and  great  apes.
Consequently  uric  acid  is  not  converted  to  readily
water  soluble  and  easily  excreted  product  allantoin,
thus  resulting  in  higher  serum  uric  acid  levels  in
humans and great apes.
1
As  early  as  in  1848 AD, Sir  Alfred  Garrod
demonstrated  that  Gout,  an  inflammatory  disease  of
joints  was  associated  with  Hyperuricemia  i.e,
increased levels of serum uric acid (>7mg/dl in males
and >6mg/dl in females).
2 Gout is a disease of joints
characterised by the deposition of monosodium urate
crystals  in  joint  space  causing  inflammation  and
painful joints.
A few years later, in 1874 AD, Frederick Mohamed
postulated  for  the  first  time  that  “People  with high
blood  pressure  belong  to  gouty  families”  suggesting
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the  possible  association  of  Hyperuricemia  with  high
blood pressure.
3
Association  of  elevated  serum  uric  acid  with
hypertension  was  further  reported  by  many
researchers.  At  the  end  of the  19th  century many
studies demonstrated that uric acid was also associated
with cardiovascular  morbidity.  However,  lack  of
possible mechanism by which hypertension and uric
acid are associated led to conclusion that uric acid is
not a true risk factor for cardiovascular disease.
4-9
Amidst contradicting reports, Mohamed’s hypothesis
that  uric  acid  has  a  causative  role  in  hypertension
remains controversial even after over 130 years.
Recent  animal  studies  and  clinical  observations
indicate the possible direct causal role of uric acid in
pathogenesis  of  hypertension  by  various
mechanisms.
10 Of  late,  increasing  evidence  is  being
gathered suggestive of association and causal role of
uric  acid in hypertension  and  cardiovascular
morbidity.
11
Hitherto  studies  conducted  have  not  assessed  the
association of serum uric acid levels blood pressure in
prehypertensives and  its  incremental  rise  with
increasing blood pressure. So in this study we intend
to assess the association of serum uric acid levels with
blood pressure in normotensive, prehypertensive and
hypertensive  participants.  We  also  intend  to  check
whether there is an incremental rise of serum uric acid
with increasing blood pressure.
MATERIALS AND METHODS
Our study was  conducted  at  Regional Diagnostic
Laboratory  of  District  Hospital,  Bidar,  a  teaching
hospital  affiliated  to the  Bidar  Institute of  Medical
Sciences,  Karnataka,  India. Study  spanned  over  a
period  of  3  months from August to October 2013.
Institutional  Ethical  committee  approval was  taken
before  commencement  of  study and  our  procedures
were in accordance with the Helsinki Declaration of
1975, as revised in 2000.
12
The  subjects  for  this  prospective  study  were
outpatients who visited regional diagnostic laboratory
for  routine  investigations. Two  hundred  participants
(103 men and 97 women) of age group 20 to 60 years
formed the study population.
Subjects who fulfilled below mentioned inclusion and
exclusion criteria were informed and explained about
the study and after their informed written consent were
included in the study.
Inclusion  and  exclusion  criteria: Paediatric and
psychiatric patients, pregnant women, diagnosed cases
of essential secondary hypertension, medications like
uricosuric  drugs  and  antihypertensive  drugs were
excluded in the study.
Study participants were made to sit comfortably on a
chair  for  five  minutes. Systolic  and  diastolic  blood
pressures were measured twice by auscultatory method
with a mercury sphygmomanometer (cuff size, 12.5 x
40 cm) on the right arm. The first and fifth phases of
Korotkoff’s sounds were taken as the criteria for SBP
and DBP respectively. The mean of two consecutive
readings was recorded and used for analysis.
13 Mean
of systolic and diastolic blood pressure was calculated
(SBP+DBP/2) and noted as mean blood pressure.
As per Joint National Committee (JNC)
7 classification
of  blood  pressure,  Participants  were  categorised  as
normal if systolic blood pressure (SBP) was <120mm
of Hg and Diastolic blood pressure (DBP) was <80mm
of Hg; prehypertensive if SBP/DBP is 120-139/or 80-
89 mm of Hg; Stage 1 Hypertensive if SBP/DBP is
140-159/or 90-99mm of Hg and were categorised as
Stage  2  hypertensives  if  SBP/DBP  is ≥160/or ≥100
mm of Hg.
14
Under  aseptic  precautions,  venipuncture  was
performed on median cubital vein and 2ml of blood
was collected into a sterile evacuated plastic tube with
red  stopper  with  no  additives. Blood  samples  were
allowed to clot at room temperature for 30 minutes.
Samples were centrifuged at 1500g for 15 minutes for
serum separation.
15
Serum  uric  acid  levels  were  measured  by modified
Trinder’s  method
16, 17 using ERBA  XL  300  fully
automated analyser. To ensure quality, daily internal
quality  control  samples  were  run  and  day  to  day
coefficient of variance (CV) was <5%. The laboratory
also had an external quality assurance programme in
place.
Statistical Analysis: Statistical analysis of participant
data was performed using “IBM SPSS Statistics 20”
software. The data was analysed to measure age-sex
distribution of participants, to categorise participants
as normal, prehypertension, Stage-1 hypertension and
stage-2  hypertension along  with  their  mean  blood
pressures and mean serum uric acid levels. Pearson’s
correlation coefficient was calculated to elucidate the
statistically significant association between serum uric
acid levels and blood pressure.
18106
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RESULTS
Characteristics of study population: The demographic
characteristics of the study population are summarised
in  table 1. Study  population  comprised  of  200
participants  of  whom  103  were  men  and  97  were
women..
Table: 1. Age sex distribution of study population
with mean blood pressure
Age
(years)
Number
of Males
Number
of females
Blood pressure*
(mm of Hg)
20 - 30 35 44 98.08 ± 9.09
31 - 40 14 14 101.96 ± 13.13
41 - 50 17 15 107.21 ± 14.27
51 - 60 37 24 112.23 ± 12.69
* mean ± standard deviation
Mean  age  of  the  study  population  was  40.06±13.8
years and mean age of males and females was 41.98 ±
13.48 years and 38.03 ± 13.91 years respectively. The
mean blood pressure of study population showed an
increasing trend with age
The  prevalence of  undiagnosed  hypertension  in
population  was  22%  (n = 44)  and  of undiagnosed
prehypertension  was  42% (n = 84),  put  together
comprising  nearly  65%  of study  population. A
stepwise  increase  in  serum  uric  acid  levels  was
observed when study population was categorised into
four  groups  namely, Normal,  Prehypertension,
Hypertension stage-1, Hypertension stage-2 based on
the  JNC  7  classification of  blood  pressure. Similar
increasing  trend in  mean  serum  uric  acid  level  was
observed along with mean blood pressure of the study
population. (Table-2)
Table: 2. Serum uric acid and blood pressure in normotensives, prehypertensives and hypertensives
JNC 7 BP classification
14
(SBP/DBP mm of Hg)
Males Females
Serum Uric acid*
(mg/dl)
Blood Pressure*   (mm
of Hg)
Normal
(<120/ and <80)
30 42 5.09 ± 0.65 92.95 ± 4.7
Prehypertension
(120-139/ or 80-89)
47 37 5.70 ± 0.73 104.08 ± 5.21
Hypertension Stage-1
(140-159/ or 90-99)
18 14 6.81 ± 0.77 119 ± 6.94
Hypertension Stage-2
(≥160/ or ≥ 100)
8 4 7.59 ± 0.57 136.41 ±6.86
* mean ± standard deviation
Statistically highly significant (p<0.0001) difference in
mean serum uric acid was observed between normal
and prehypertension categories; and also  between
prehypertension  and hypertension  stage-1  JNC  7
categories.  Similar but  less  profound, statistically
significant  difference  (<0.01) was  noted  between
Stage-1 and Stage-2 hypertension categories.
A  strong  positive  linear  correlation  was  observed
between  serum  uric  acid  levels  and  mean  blood
pressure (Pearson’s correlation coefficient r = 0.74).
Correlation is highly significant at the 0.05 level (2-
tailed) and the P-value is < 0.0001. (Figure 1). Similar
correlation  was  also  noted  between  serum  uric  acid
and systolic blood pressure (r = 0.746) and diastolic
blood pressure (r = 0.609). Uric acid was associated
strongly  (r = 0.442)  with  blood  pressure  in the
prehypertension population while a weak correlation (r
= 0.113) was observed in normal population.
Fig  1: Scatter  diagram  showing  correlation  of
serum uric acid levels with mean blood pressure.
DISCUSSION
Our prospective study consisting of 200 participants
showed an association of serum uric acid with blood
pressure  in  apparently  healthy  individuals,
undiagnosed  prehypertensive  subjects  and107
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hypertensive  individuals. This  is  the  first  study
conducted  in  India  to  elucidate  the  association  of
serum  uric  acid  levels  with  blood  pressure  in
prehypertensive population.
Study population comprised of adult individuals from
20 years to 60 years. Mean age of the study population
was  40.06±13.8 years comparable to  other  similar
studies that had a mean age of 42.3±0.2 years19 and
41.6 years.
20
Although known hypertensive patients were excluded
from  the  study,  22%  (n = 44)  of  participants  were
hypertensivses  and  42%  (n = 84)  were
prehypertensives. Similar prevalence  of
prehypertension (39%) among  adults in India
21 and
Unitesd states of America
22 was reported by separate
researchers. It is noteworthy that, a large percentage of
the  population who are  at  risk  of  developing
hypertension (42%)  and  undiagnosed hypertensives
(22%) who may develop cardiovascular morbidity go
unnoticed.
Serum uric acid levels were positively (r = 0.740) and
significantly (p < 0.0001) associated  with  blood
pressure  in  our  study. A  similar  positive and
statistically  significant  correlation  was  observed  by
other researchers.
19, 20, 22, 23
A  stepwise  incremental  rise  of  serum  uric  acid  was
observed  with  increasing  blood  pressure  when
participants  were  categorised  as  per  JNC7
classification as normal, prehypertension, hypertension
stage-1,  and  hypertension  stage-2. A  similar
incremental increase of  uric  acid  was  observed in  a
cross sectional study conducted in Japan. However this
study categorised the participants based on Japanese
society  guidelines  JSH-2009  rather  than  JNC  7
classification.
19
A  similar  association (r = 0.15;  p < 0.001)  was
demonstrated  by  a  study  on  large  prospective  male
cohort. They also demonstrated that serum uric acid
was  independently  related  to  mortality  from
congestive heart failure and stroke.
20
Positive association (r = 0.32) of serum uric acid with
prehypertension  independent  of  smoking  BMI  and
other confounding factors was observed in a study.
22
A  study  demonstrated significant  (p  <  0.0001)
correlation between uric acid and prehypertension in
adults but the study also noted, unlike our study, that
the association was not statistically significant in older
individuals over 65 years of age.
23
In a nine year follow-up study, association of serum
uric acid with incident hypertension was observed and
stronger association was noted among blacks.
24
PIUMA  study,  with a  cohort of  1720  patients  with
follow-up of 12 years noted that, subjects with higher
uric  acid  levels  were  at  higher  risk  of  developing
cardiovascular  events (relative  risk 1.73;  95%
confidence interval) than the subjects with lower uric
acid levels.
25
A study on 125 children (age group 6-18 years) with
primary hypertension demonstrated the association of
serum uric acid with systolic blood pressure (r = 0.80)
and  diastolic  blood  pressure  (r = 0.66).
26 Another
study  in paediatric age  group  also  observed  the
association of serum uric acid levels with ambulatory
diastolic blood pressure (r = 0.29; p = 0.0033).
27
Serum  uric  acid  has  long  been  associated  with
hypertension, the primary aetiology of cardiovascular
morbidity.  Several  large  cohort  studies  have
demonstrated that serum uric acid was predictive of
mortality due to ischaemic heart diseases in women.
28
Few studies  demonstrated  the  independent  and
significant association of  uric  acid  with  risk  of
cardiovascular  mortality
29 and  myocardial  infarction.
30 It was observed in a study that serum uric acid level
was a  strong  and  independent  predictor of
cardiovascular mortality in middle aged men.
31
Increased serum uric acid levels have been associated
with  elevated  blood  pressure  and  cardiovascular
morbidity  and  mortality. But  the causal  role  of  uric
acid  in  hypertension  and  pathogenesis  of
cardiovascular events has not been clear.
5- 9
Recent  studies  have  elucidated  the  plausible
mechanisms that explain how elevated uric acid causes
hypertension. Studies on animal models have shown
that  increased  uric  acid  levels  cause  renal
microvascular and tubular interstitial injury. Uric acid
also  increases  juxtaglomerular  renin  production  and
decreases nitric oxide synthase expression in macula
densa;  collectively  contributing to  blood  pressure
elevation.
10
CONCLUSION
Serum  uric  acid  levels  are  associated  with
hypertension  and  are  independent  and  strong
predictors  of  cardiovascular  mortality,  myocardial
infarction and coronary artery diseases in both sexes of
different ethnic groups. So it may not an exaggeration108
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to state that “Uric acid licks the joints and bites the
heart”
Limitations of the study: The study population was
drawn from outpatients of a hospital that may not form
a  representative  sample  of the  general  population.
Confounders  like  serum  creatinine,  serum  uric  acid,
serum albumin, history of alcohol intake, and dietary
protein and sodium consumption that alter serum uric
acid  and  /or  blood  pressure were  not  taken  into
consideration.
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